Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445848 · ClinicalTrials.gov registry record · Phase 2
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT00445848: Completed Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
NCT00445848 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 89 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445848, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IIIB or stage IV primary non-small cell lung cancer who have never smoked.
Primary Outcome
From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
- DRUG erlotinib hydrochloride
Study Locations (20)
California
- Kaiser Permanente - Deer Valley - Antioch
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- Kaiser Permanente - Fremont - Fremont
- Marin Cancer Institute at Marin General Hospital - Greenbrae
- Kaiser Permanente Medical Center - Hayward - Hayward
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
- Kaiser Permanente Medical Center - Oakland - Oakland
- Valley Medical Oncology Consultants - Pleasanton - Pleasanton
- Kaiser Permanente Medical Center - Redwood City - Redwood City
- Kaiser Permanente Medical Center - Richmond - Richmond
- Kaiser Permanente Medical Center - Roseville - Roseville
- University of California Davis Cancer Center - Sacramento
- South Sacramento Kaiser-Permanente Medical Center - Sacramento
- Kaiser Permanente Medical Center - Sacramento - Sacramento
- Kaiser Permanente Medical Center - San Francisco Geary Campus - San Francisco
- California Pacific Medical Center - California Campus - San Francisco
- Kaiser Permanente Medical Center - Santa Teresa - San Jose
- Kaiser Foundation Hospital - San Rafael - San Rafael
- Sutter Health - Western Division Cancer Research Group - San Rafael
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2007-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
What the finished NCT00445848 record still lists
NCT00445848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.
NCT00445848 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT00445848 about?
NCT00445848 is a clinical study titled "S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them o...
What is the current status of trial NCT00445848?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2007-07. Estimated completion is 2014-01.
What conditions does trial NCT00445848 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00445848?
The interventions under investigation include: bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00445848?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00445848 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00445848's enrollment target sits among peer trials
89 205th of 409 higher than 205 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia